Is Dyslipidemia a Risk Factor for Trastuzumab-induced Cardiotoxicity in Breast Cancer Patients? A Systematic Review and Meta-Analysis
Background: Breast cancer patients undergoing trastuzumab treatment have greater risk of cardiovascular disease. Several risk factors for this effect have been proposed. However, the role of dyslipidemia is not completely known. This PRISMA-guided systematic review and meta-analysis aimed to explore...
| Autor principal: | |
|---|---|
| Formato: | masterThesis |
| Idioma: | por |
| Publicado em: |
2021
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/134558 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/134558 |